It has been confirmed [13] in ESCC that LRIG1 as a candidate tumor suppressor gene could feedback the high expression of inhibition of EGFR, and by increasing the high expression level of LRIG1, EGFR pathway for therapeutic intervention, therefore effectively reduces the EGFR expression levels, which provide new ideas for the clinical treatment of esophageal cancer. The gene discussed is EGFR; the disease is esophageal cancer.